Literature DB >> 644316

Myoadenylate deaminase deficiency: a new disease of muscle.

W N Fishbein, V W Armbrustmacher, J L Griffin.   

Abstract

Five cases of a new disease presented with muscular weakness or cramping after exercise; three of the cases also had an elevated serum creatine phosphokinase. Muscle biopsies were histologically normal but lacked adenylate deaminase by stain and solution assay, while the erythrocyte isozyme was normal. A clinical diagnostic test has been developed, and the human enzyme was separated by acrylamide-gel electrophoresis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 644316     DOI: 10.1126/science.644316

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  49 in total

1.  Muscle metabolism and red cell ATP/ADP concentration during bicycle ergometer in patients with AMPD-deficiency.

Authors:  D R Wagner; J Felbel; U Gresser; N Zöllner
Journal:  Klin Wochenschr       Date:  1991-04-04

2.  Type 2a fibre rhabdomyolysis in myoadenylate deaminase deficiency.

Authors:  C Zimmer; H Altenkirch; S Dorfmüller-Küchlin; D Pongratz; I Paetzke; G Gosztonyi
Journal:  J Neurol       Date:  1991-02       Impact factor: 4.849

3.  Developmental forms of human skeletal-muscle AMP deaminase. The kinetic and regulatory properties of the enzyme.

Authors:  K Kaletha; G Nowak
Journal:  Biochem J       Date:  1988-01-01       Impact factor: 3.857

4.  Purine biosynthesis de novo in rat skeletal muscle.

Authors:  T G Sheehan; E R Tully
Journal:  Biochem J       Date:  1983-12-15       Impact factor: 3.857

Review 5.  Molecular biology of AMP deaminase deficiency.

Authors:  M Gross
Journal:  Pharm World Sci       Date:  1994-04-15

6.  Neonatal rotavirus infection.

Authors:  M Santosham; A Pathak; S Kottapalli; J Vergara; S J Wong; J Frochlick; R B Sack
Journal:  Lancet       Date:  1982-05-08       Impact factor: 79.321

7.  Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect.

Authors:  H Morisaki; T Morisaki; L K Newby; E W Holmes
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle.

Authors:  R L Sabina; J L Swain; C W Olanow; W G Bradley; W N Fishbein; S DiMauro; E W Holmes
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

9.  Disruption of the purine nucleotide cycle. A potential explanation for muscle dysfunction in myoadenylate deaminase deficiency.

Authors:  R L Sabina; J L Swain; B M Patten; T Ashizawa; W E O'Brien; E W Holmes
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

10.  The oxidative pentose phosphate pathway in the heart: regulation, physiological significance, and clinical implications.

Authors:  H G Zimmer
Journal:  Basic Res Cardiol       Date:  1992 Jul-Aug       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.